Lab
Pyxant Labs INC
Pyxant Labs INC was paid $1.19M by Medicaid between Jan 2018 and Mar 2020, across 44 billing codes. Its largest line is 80307, Drug test(s), presumptive, any number of drug classes; immunoassay — 7.5% of everything it billed.
33Billing provider infoPYXANT LABS INC
COLORADO SPRINGS, CO 80907
COLORADO SPRINGS, CO 80907
33aNPI1386003598assigned 02/16/2016
33bProvider typeClinical Medical Laboratory
28Total paid$1.19M
24GClaims83,545
24DCodes billed44
24AFirst – last monthJan 2018 – Mar 2020
Compared with peers
Next to other Clinical Medical Laboratory providers in Colorado
Rank by total paid#22 of 91
Median peer was paid$53K
This provider vs. median22×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 21,378 | $240K | |
| 2019 | 55,230 | $838K | |
| 2020 | 6,937 | $112K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 7.5% | 7,467 | 4,998 | $89K |
| 80373 | 6.9% | 5,471 | 3,341 | $82K | |
| 80354 | 6.9% | 5,487 | 3,356 | $82K | |
| 80372 | 6.9% | 5,388 | 3,285 | $82K | |
| 80360 | 6.6% | 5,259 | 3,174 | $79K | |
| 80357 | 5.9% | 4,355 | 2,304 | $71K | |
| 80350 | 5.0% | 3,693 | 1,670 | $60K | |
| 80324 | 5.0% | 3,639 | 1,766 | $60K | |
| 80367 | 4.8% | 3,525 | 1,503 | $57K | |
| 80323 | 4.0% | 2,917 | 1,609 | $47K | |
| 80363 | 3.6% | 2,726 | 1,636 | $43K | |
| 80371 | 3.5% | 2,577 | 1,161 | $42K |
32 more codes
| 80364 | 3.3% | 2,676 | $39K | |
| 80346 | 2.4% | 2,103 | $28K | |
| 80368 | 2.1% | 1,562 | $25K | |
| 80361 | 2.1% | 1,884 | $25K | |
| 80365 | 2.0% | 1,909 | $24K | |
| 80349 | 1.9% | 1,467 | $23K | |
| 80359 | 1.7% | 1,702 | $20K | |
| 80348 | 1.7% | 1,514 | $20K | |
| 80325 | 1.7% | 1,646 | $20K | |
| 80377 | 1.5% | 1,078 | $18K | |
| 80355 | 1.5% | 1,291 | $17K | |
| 80356 | 1.3% | 1,373 | $16K | |
| 80358 | 1.3% | 1,342 | $15K | |
| 80353 | 1.1% | 1,028 | $13K | |
| 80321 | <1% | 727 | $12K | |
| 80332 | <1% | 695 | $11K | |
| 80345 | <1% | 971 | $11K | |
| 83992 | <1% | 890 | $11K | |
| 80342 | <1% | 637 | $10K | |
| 80370 | <1% | 647 | $10K | |
| 80366 | <1% | 760 | $9K | |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 1,880 | $6K |
| 80369 | <1% | 296 | $5K | |
| 80338 | <1% | 284 | $4K | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 401 | $2K |
| 80374 | <1% | 46 | $726.11 | |
| 80335 | <1% | 28 | $480.79 | |
| 80337 | <1% | 29 | $37.17 | |
| 80339 | <1% | 30 | $37.17 | |
| 80343 | <1% | 30 | $37.17 | |
| 80351 | <1% | 37 | $10.61 | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 0% | 78 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGAUBATZ, MAURICE (OWNER CEO)